Inclacumab was generally well tolerated in THRIVE-131
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Phase 1 dosing is expected to finish by the end of 2025
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Subscribe To Our Newsletter & Stay Updated